James William Rogers Sells 10,853 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,853 shares of Tempus AI stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $478,291.71. Following the completion of the transaction, the chief financial officer owned 126,395 shares in the company, valued at $5,570,227.65. The trade was a 7.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $46.18 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of -26.85 and a beta of 3.99. The stock’s fifty day simple moving average is $48.89 and its 200 day simple moving average is $59.29. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company’s quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TEM. Mizuho began coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. HC Wainwright lowered their price target on Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. JPMorgan Chase & Co. lowered their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Morgan Stanley lowered their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Finally, Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. JPL Wealth Management LLC acquired a new stake in Tempus AI during the third quarter valued at $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the third quarter valued at $38,000. Whittier Trust Co. boosted its position in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at $42,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.